FDA ad­comm votes in fa­vor of new an­ti­fun­gal; De­nali gets $25M from Sanofi MS tri­al mile­stone

The FDA’s An­timi­cro­bial Drugs Ad­vi­so­ry Com­mit­tee vot­ed 14-1 in fa­vor of a lim­it­ed-use in­di­ca­tion for Cidara Ther­a­peu­tics’ reza­fun­gin, a treat­ment for can­didemia and in­va­sive can­didi­a­sis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER